JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

Introduction: JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted Listeria monocytogenes–based immunotherapy expressing human mesothelin. JNJ-757 was evaluated in patients with advanced NSCLC as monotherapy (phase 1) and in combination with nivolumab (phase 1b/2). Methods: Patients with sta...

Full description

Bibliographic Details
Main Authors: Julie R. Brahmer, MD, Melissa L. Johnson, MD, Manuel Cobo, MD, PhD, Santiago Viteri, MD, Juan Coves Sarto, MD, Ammar Sukari, MD, Mark M. Awad, MD, PhD, Ravi Salgia, MD, PhD, Vali A. Papadimitrakopoulou, MD, Arun Rajan, MD, Nibedita Bandyopadhyay, PhD, Alicia J. Allred, PhD, Mark Wade, MA, Gary E. Mason, MD, Enrique Zudaire, PhD, Roland E. Knoblauch, MD, PhD, Nicole Stone, PhD, Matthew V. Lorenzi, PhD, Raffit Hassan, MD
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
Mesothelin
LADD Lm
JNJ-757
Vaccine
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301491

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301491

Similar Items